A lipid-lowering agent. Reversibly inhibits HMG-COA reductase, inhibits the cholesterol synthesis at the stage of mevinolinic acid and moderately reduces its intracellular concentration. The indications for the drug use include: primary hypercholesterolemia mainly of IIa and IIb types, under the ineffective diet treatment in patients with increased risk of coronary atherosclerosis, hypercholesterolemia combined with hypertriglyceridemia; prevention of coronary artery disease. The drug decreases the risk of myocardial infarction, the need for revascularization of the myocardium, deaths from cardiovascular system diseases.

BCCC; a derivative of diphenylalkylamine. Has antianginal, anti-arrhythmic and hypotensive effect. The antianginal effect is associated with both direct action on the myocardium and with the effect on peripheral hemodynamics. It is prescribed with stenocardia, supraventricular tachycardia, sinus tachycardia, ciliary tachyarrhythmia, atrial flutter, atrial extrasystole, arterial hypertension, GOKMP, primary hypertension in the "small" circle of the circulation.